Table 2.
CCLG-2008 treatment protocol
| CCLG-2008 | Prednisoneinduction | Remission induction | Early intensification | Consolidation | Delay intensification I | Maintenance I | Delay intensification II | Maintenance II |
|---|---|---|---|---|---|---|---|---|
| Standard risk | P (1 week) | VDLD (DNR ×2) | CAM | HD-MTX (2 g/m2) ×4 | VDLD + CAM | – | – | 6-MP + MTX/VD + IT |
| Intermediate risk | P (1 week) | VDLD (DNR ×4) | CAM ×2 | HD-MTX (5 g/m2) ×4 | VDLD + CAM | 6-MP + MTX | VDLD + CAM | 6-MP + MTX/VD + TIT |
| High risk | P (1 week) | VDLD (DNR ×4) | CAM ×2 | I′II′III′ ×2 | VDLD + CAM | – | – | 6-MP + MTX/CA/VD + IT |
Notes: I′, BFM high-risk block-1′; II′, BFM high-risk block-2′; III′, BFM high-risk block-3′.
Abbreviations: CCLG, Chinese Childhood Leukemia Group; VDLD, vincristine + daunorubicin + l-asparaginase + dexamethasone; CAM, cyclophosphamide + cytarabine + 6-mercaptopurine; HD-MTX, high-dose methotrexate; 6-MP, 6-mercaptopurine; VD, vincristine + dexamethasone; IT, intrathecal injection with dexamethasone and methotrexate; CA, cyclophosphamide + cytarabine; TIT, intrathecal injection with dexamethasone, methotrexate, and cytarabine; BFM, Berlin-Frankfurt-Münster; DNR, daunorubicin.